Condition: Colorectal Neoplasms · Sponsor: Federation Francophone de Cancerologie Digestive
Colorectal cancer is the 3rd most common cancer in France and the 2nd cause of death from cancer. Between 30 to 60% of patients develop limited or predominant liver metastases. Surgical resection of these metastases, only curative treatment is not immediately possible in 10-15% of cases. In unresectable patients, current palliative treatments are based on systemic chemotherapy associated or not with the targeted therapies (anti-EGFR (panitumumab), anti-VEGF (bevacizumab)). In this patient population, special attention was paid to intensified treatment regimens in order to improve their efficiency and improving the tumoral response rate, the intensity of the response and its earliness correlate with improved overall and progression-free survival. The intra-arterial use of oxaliplatin coupled with IV chemotherapy has yielded OR levels of 64% in patients having survived one or more lines of chemotherapy IV and 62% in patients who have progressed on oxaliplatin IV. In addition, the HIA administration of oxaliplatin limits systemic and especially neurological toxicities, thanks to a greater hepatic clearance. In conclusion, the combination of systemic chemotherapy, targeted therapy and HIAC with oxaliplatin has showed promising efficacy results associated with good tolerance from the first line onwards. Indeed, we can expect from the Phase II recent data, a control rate close to 100%, with high response rates associated with early maturity and depth responses as well as prolonge…
This description comes directly from the study's public registry record.
Sofia JOURDAN · +33 (0)380393404 · sofia.jourdan@u-bourgogne.fr
Marie MOREAU · +33(0)3 80 39 32 36 · marie.moreau@u-bourgogne.fr
Always discuss trial participation with your own doctor first.
| Hôpital Erasme | Brussels, Belgium | Recruiting |
| Chu Hotel Dieu | Angers, France | Recruiting |
| Institut de Cancérologie de l'Ouest | Angers, France | Recruiting |
| Hôpital Privé d'Antony | Antony, France | Recruiting |
| CH Henri Duffaut | Avignon, France | Not Yet Recruiting |
| Institut du cancer Avignon Provence | Avignon, France | Recruiting |
| Ch Cote Basque | Bayonne, France | Recruiting |
| Clinique Belharra | Bayonne, France | Recruiting |
| Centre Hospitalier | Beauvais, France | Not Yet Recruiting |
| Institut Bergonié | Bordeaux, France | Recruiting |
| Polyclinique Bordeaux Nord | Bordeaux, France | Recruiting |
| Infirmerie Protestante de Lyon | Caluire-et-Cuire, France | Recruiting |
+ 37 more locations — full list on the registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT02885753